Implementation status of pharmacological studies in the development of orphan drugs

Saki Yokoshiki,Teruyo Arato

DOI: https://doi.org/10.1186/s13023-023-03000-0

2024-01-05

Orphanet Journal of Rare Diseases

Abstract:The nonclinical as well as clinical development of orphan drugs is difficult, owing to unknown pathophysiology and the absence of animal models. Both, the U.S. Food and Drug Administration (FDA) Guidance and European Medicines Agency (EMA) Guidelines, for orphan drug development describe non-clinical studies, but lack specific information, such as animal species and study design. Against this background, this study aimed to elucidate efficient methods for evaluating nonclinical efficacy based on a review report of orphan drugs approved in Japan.

genetics & heredity,medicine, research & experimental

What problem does this paper attempt to address?

### What problems does this paper attempt to solve?

This paper aims to solve the challenges encountered in the non - clinical research and development process of orphan drugs (drugs for rare diseases). Specifically, the author hopes to clarify how to evaluate the effectiveness of drugs by flexibly designing non - clinical studies through reviewing the data packages and pharmacological study designs of orphan drugs approved in Japan between 2010 and 2019, thereby promoting clinical development.

#### Background and problems
1. **Difficulties in orphan drug development**:
- The non - clinical and clinical development of orphan drugs faces many challenges, mainly because the pathophysiological mechanisms of rare diseases are not fully understood and there is a lack of suitable animal models.
- The orphan drug development guidelines issued by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) describe non - clinical studies, but lack specific guidance information, such as animal species and study design.

2. **Research purposes**:
- By analyzing the non - clinical study data of orphan drugs approved in Japan, explore how to flexibly design non - clinical studies according to disease characteristics to evaluate the effectiveness of drugs.
- Clarify whether these methods can support the approval of orphan drugs, although these methods are not described in detail in the EMA guidelines or FDA guidelines.

#### Methods
- Research objects: 184 orphan drugs approved in Japan from January 2010 to December 2019, including 84 anti - cancer drugs and 100 non - anti - cancer drugs.
- Data sources: Obtain relevant drug review reports from the website of the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan.
- Analysis contents:
- Anti - cancer drugs: Evaluate the design of in vitro and in vivo pharmacological studies and their relationship with clinical trial inclusion criteria or approved indications.
- Non - anti - cancer drugs: Evaluate the animal species and endpoints used in in vivo studies and analyze the relationship between clinical and non - clinical endpoints.

#### Main findings
1. **Anti - cancer drugs**:
- Some anti - cancer drugs failed to clearly show effectiveness in non - clinical studies but still entered the clinical development stage. For example, some drugs were studied only using patient - derived cells because of the lack of established cell lines.
- For drug - resistant tumors or tumors with specific amino acid mutations, cell lines with corresponding mutations were used for non - clinical evaluation.
- For solid tumors with specific biomarkers, multiple cancer cell lines were used for in vitro studies.

2. **Non - anti - cancer drugs**:
- Due to the lack of animal models for target diseases, the efficacy evaluation of many non - anti - cancer drugs depends on normal animals or animal models of similar diseases.
- Some drugs' efficacy evaluation used biomarkers.

#### Conclusions
- By flexibly designing non - clinical studies, the efficacy of orphan drugs can be effectively evaluated according to disease characteristics, which helps to promote the clinical development and final approval of drugs.
- Although these methods are not described in detail in the existing EMA guidelines or FDA guidelines, they may be of great significance for the development of orphan drugs in practical applications.

In conclusion, this paper attempts to solve the specific problems of non - clinical study design in orphan drug development and proposes a flexible and effective evaluation method to promote the rapid development and approval of orphan drugs.